scholarly journals Effectiveness of the Cataract Prevention in Patients with Epiretinal Membrane after Vitrectomy

2020 ◽  
Vol 17 (4) ◽  
pp. 811-816
Author(s):  
V. V. Dashina ◽  
V. A. Porhanov ◽  
A. V. Malyshev ◽  
S. V. Yanchenko ◽  
Z. Z. Al-Rashyd ◽  
...  
Keyword(s):  
Epiretinal Membrane ◽  
Control Points ◽  
High Efficacy ◽  
Corrected Visual Acuity ◽  
Group Data ◽  
Before And After ◽  
Ophthalmologic Examination ◽  
Cataract Development ◽  
The Mean ◽  
Lens Opacities

Purpose: tо evaluate effectiveness of cataractogenesis prophylaxis in patients with epiretinal membrane (ERM) after vitrectomy based on the pirenoxin use.Patients and мethods. The study included 72 patients (64.5 ± 6.4 years old; 31 men, 41 women) with ERM before and after 25G microinvasive vitrectomy with removal of ERM. The 1-st group patients (36 eyes) received pirenoxin instillation (Catalin®; 3 times a day, 6 months) in addition to the standard pharmacological support. The 2-nd group patients received only standard therapy. All patients underwent: standard ophthalmologic examination; lens state photoregistration with an assessment of lens opacities intensity (LOCS-III classification) with the calculation of the cataract development index (CDI). These were control points: examination before vitrectomy and 5 months after surgery. At control points, the incidence of lens opacities in the observation groups was also evaluated. Statistical analysis included: calculation of the mean and its standard deviation (M ± s); assessment of the significance of differences in control points with each group (Wilcoxon's T-test) and between groups (Mann—Whitney U-test); Pearson xi-square test.Results: In the 1-st group (pirenoxin instillation), 6 months after vitrectomy and ERM removal, the following indicators were noted: the initial cataract incidence was 5.6 %; CDI — 0.36 ± 0.03 points, increasing the maximum corrected visual acuity (MCVA) from 0.31 ± 0.03 to 0.6 ± 0.05. In the 2-nd group similar indicators significantly differed from the 1-st group data: the initial cataract incidence was 36.1 % (Pearson xi-square test > 3; p < 0.05); CDI — 3.1 ± 0.3 points (p < 0.01); the MCVA increase from 0.3 ± 0.05 to 0.43 ± 0.1 (p < 0.05).Conclusion. Pirenoxin (Catalin®) has demonstrated quite high efficacy in the cataract prevention in patients after vitrectomy with ERM removal. 

scholarly journals Retinal Sensitivity before and after Silicone Oil Removal Using Microperimetry

2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Ghada A. Nassar ◽  
Maha M. Youssef ◽  
Lameece M. Hassan ◽  
Hebatalla S. Makled
Keyword(s):  
Silicone Oil ◽  
Retinal Sensitivity ◽  
Oil Removal ◽  
Corrected Visual Acuity ◽  
Significant Difference ◽  
Before And After ◽  
Group A ◽  
The Mean ◽  
Group B ◽  
Best Corrected Visual Acuity

The purpose of the study is to assess the retinal sensitivity, using microperimetry, before and after silicone removal. It included 22 patients admitted for silicone removal after vitrectomy for macula-off retinal detachment. Patients were divided into 2 groups according to the duration of silicone tamponade: Group A: <3 months (included 10 patients), and Group B: 3–6 months (included 12 patients). Retinal sensitivity was tested, using microperimetry, one day before and one month after silicone removal. The best-corrected visual acuity (in LogMAR) significantly improved postoperatively (0.69 versus 1.06 and 0.69 versus 1.07 in Groups A and B, respectively). The mean intraocular pressure (IOP) was 12.89 ± 1.05 mmHg postoperatively versus 14.89 ± 1.76 mmHg preoperatively in Group A (p=0.011) and was 13.33 ± 1.30 mmHg postoperatively versus 15.33 ± 3.11 mmHg preoperatively in Group B (p=0.008). In Group A, the mean postoperative overall retinal sensitivity was 8.70 ± 2.56 dB versus 5.68 ± 2.00 dB preoperatively (p=0.008). In Group B, it was 9.83 ± 3.36 dB versus 7.00 ± 2.55 dB (p=0.002). No statistically significant difference was found between the two groups as regards improvement in overall retinal sensitivity. We concluded that the overall retinal sensitivity significantly increased following silicone removal in both groups. This trial is registered with ISRCTN43187564.

Neovaskulinės amžinės geltonosios dėmės degeneracijos gydymo ranibizumabu 24 mėnesių morfologiniai ir funkciniai pokyčiai

2015 ◽  
Vol 21 (3.2) ◽  
pp. 413-416
Author(s):  
Vilma Jūratė Balčiūnienė ◽  
Rosita Lažaunykaitė
Keyword(s):  
Visual Acuity ◽  
Macular Thickness ◽  
Age Related Macular Degeneration ◽  
Central Macular Thickness ◽  
Corrected Visual Acuity ◽  
Age Related ◽  
Before And After ◽  
The Mean ◽  
The Difference ◽  
Best Corrected Visual Acuity

Key words: ranibizumab, age-related macular degeneration, central macular thickness. Research objective. To evaluate influence of treatment with vascular endothelial growth factor inhibitor, ranibizumab, for best corrected visual acuity and central macular thickness in patients with neovascular age-related macular degeneration. Materials and methods. In this retrospective study were included treatment – naive patients. Intravitreal injections were performed at Lithuanian University of Health Sciences Kaunas Clinics Eye clinic. In this study were analysed the 24-month morphological and functional outcomes of intravitreal ranibizumab injections. Best corrected visual acuity was meassured using the Snellen chart (Landolt’s rings C optotypes). Optical coherence tomography images were obtained using the spectral – domain OCT (NIDEK RS – 3000 Advance (NIDEK CO LTD, Japan). The central thickness measurements were obtained from macular thickness maps using the digital caliper tool. Results. In this study were included 88 patients. Best corrected visual acuity before treatment was 0.36 ± 0.22. The difference between visual acuity before and after first injection was 0.04 ± 0.22 (p = 0.03). Before fifth injection visual acuity was 0.41 ± 0.21, after – 0.46 ± 0.22 (p = 0.05). Central macular thickness before treatment was 297.81 ± 106.04 μm. The difference between central macular thickness before and after first injection was 85.21 ± 113.37 μm (p &lt; 0.001). Before second injection central macular thickness was 273.57 ± 87.49 μm, after – 234.51 ± 58.96 μm (p = 0.002). Before fourth injection central macular thickness was 237.20 ± 40.87 μm, after – 219.10 ± 42.26 μm (p = 0.04). The mean central macular thickness significantly decreased from 298.15 ± 104.78 to 229.08 ± 56.57 (p &lt; 0.001). In 24 month of treatment the average number of ranibizumab injections was 3.61 ± 1.55. Conclusions. Our study’s results showed that over 24 month best corrected visual acuity improvement was statistically significant after first and fifth injection. Baseline compared with last injection, there was not statistically significant difference. Central macular thickness improvement statistically significant was after first, second and fourth injection. There was statistically significant decreased baseline compared with the last injection. The mean number of ranibizumab injections was 3.61 ± 1.55 in 24 month.

scholarly journals Correlations among metamorphopsia test scores, optical coherence tomography findings and multifocal electroretinogram responses in epiretinal membrane patients

2021 ◽  
Author(s):  
Jung Woo Lee ◽  
Sung Yong Park ◽  
Patrick S. Kim ◽  
In Hwan Cho ◽  
Hoon Dong Kim
Keyword(s):  
Optical Coherence Tomography ◽  
Test Scores ◽  
Epiretinal Membrane ◽  
Retinal Thickness ◽  
Multifocal Electroretinogram ◽  
Optical Coherence ◽  
Topographic Map ◽  
Corrected Visual Acuity ◽  
The Mean ◽  
The Individual

Abstract Purpose To quantify metamorphopsia with a novel objective method in patients with epiretinal membrane (ERM) and to compare the relationships among metamorphopsia scores, spectral-domain optical coherence tomography (OCT) findings, and multifocal electroretinogram (mfERG) results. Methods This study included 52 eyes of 52 patients with idiopathic ERM who underwent comprehensive ophthalmologic examinations, including measurement of best-corrected visual acuity (BCVA), OCT, and mfERG. The degree of metamorphopsia was quantified using MonPack One® (Metrovision, Perenchies, France). On the topographic map of the early treatment diabetic retinopathy (ETDRS) grid, retinal thickness in the central, superior, inferior, nasal, and temporal subfields were measured, and metamorphopsia scores for each corresponding subfield were also obtained. The amplitudes and implicit times of mERG were elicited from each subfield. Then, the correlations among metamorphopsia scores, OCT findings, and mfERG responses were analyzed. Results The mean age of the patients was 65.3 ± 18.5 y, and the average metamorphopsia score of the individual subfields was 2.03 ± 1.18. Initial BCVA was 0.50 ± 0.12 logMAR, but there was no significant correlation between metamorphopsia scores and BCVA. The metamorphopsia scores from the central subfields showed significant correlations with central retinal thickness (CRT) (p = 0.001). The mean metamorphopsia scores in the central subfield showed a significant relationship with the mean N1 and P1 amplitudes (p = 0.001, p = 0.048, respectively), while no relationship was observed between metamorphopsia scores and mfERG amplitudes in other subfields. Conclusions The degree of metamorphopsia in patients with ERM could be objectively quantified in each subfield using a novel metamorphopsia test. The metamorphopsia scores were significantly correlated with retinal thickness, especially at the central subfields, and the scores in the central subfields were significantly correlated with the N1 and P1 amplitudes of mfERG. Thus, the metamorphopsia test can be a useful method to evaluate metamorphopsia symptoms for patients with ERM.

scholarly journals Long-term outcomes of prediction error after combined phacoemulsification and trabeculectomy in glaucoma patients

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yeon Soo Kang ◽  
Mi Sun Sung ◽  
Hwan Heo ◽  
Yong Sok Ji ◽  
Sang Woo Park
Keyword(s):  
Risk Factors ◽  
Prediction Error ◽  
Anterior Segment ◽  
Anterior Chamber Depth ◽  
Absolute Error ◽  
Long Term Outcomes ◽  
Corrected Visual Acuity ◽  
Before And After ◽  
The Mean

Abstract Background To investigate long-term outcomes of prediction error after phacotrabeculectomy and to determine risk factors that may cause unstable prediction error after phacotrabeculectomy in glaucoma patients. Methods A total 120 eyes of 120 patients who had underwent uncomplicated phacotrabeculectomy (combined group) or phacoemulsification (phaco-only group) were included. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) were measured before and after surgery, and anterior segment parameters including anterior chamber depth (ACD), lens vault (LV), and anterior vault (AV) measured using anterior-segment optical coherence tomography were compared between the two groups. The mean absolute error (MAE) at 3, 6, 12, and 24 months postoperatively were compared. Risk factors associated with unstable prediction error (MAE ≥ 0.5) were investigated in the combined group. Results In both groups, BCVA was improved and IOP was decreased significantly. MAE at 3, 6, 12, 24 months postoperatively were not significantly different between two groups. The risk factors for unstable prediction error after 12 months of phacotrabeculectomy were old age and LV. Whereas, the only factor predicting unstable prediction error after 24 months of phacotrabeculectomy was LV. The cut-off value of LV for predicting unstable refractive error analyzed by the ROC curve was 0.855 mm. Conclusions Phacotrabeculectomy may be an effective treatment with stable long-term outcomes of prediction error similar to phacoemulsification in patients with glaucoma. However, elderly patients or patients with large LV may be predisposed to unstable prediction error after phacotrabeculectomy.

scholarly journals Two-year Changes in Postoperative Central Macular Thickness and Subfoveal Choroidal Thickness in Epiretinal Membrane Patients

2021 ◽  
Vol 62 (12) ◽  
pp. 1607-1616
Author(s):  
Woo Seok Choi ◽  
Jihae Park ◽  
Kyoo Won Lee ◽  
Hyun Gu Kang
Keyword(s):  
Epiretinal Membrane ◽  
Choroidal Thickness ◽  
Macular Thickness ◽  
Control Group ◽  
Central Macular Thickness ◽  
Subfoveal Choroidal Thickness ◽  
Corrected Visual Acuity ◽  
Significant Difference ◽  
The Mean

Purpose: To evaluate changes in central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) after phacovitrectomy over a 2-year period in idiopathic epiretinal membrane (ERM) patients.Methods: The records of 52 idiopathic ERM patients (52 eyes) who underwent phacovitrectomy, without recurrence of the condition over a 2-year follow-up period, were reviewed retrospectively. Changes in CMT and SFCT, as measured by optical coherence tomography, were analyzed and compared with those of a normal control group over a 2-year period.Results: The mean preoperative CMT and SFCT were 425.67 ± 84.67 and 257.56 ± 90.13 μm, respectively. Postoperative CMT was reduced significantly to 372.17 ± 45.26 μm at 1 year and 363.15 ± 47.35 μm at 2 years (p < 0.001). SFCT at 1 and 2 years postoperatively was significantly reduced to 238.85 ± 84.85 and 230.31 ± 87.95 μm, respectively (p < 0.001). In the control group, there was no significant change in CMT; however, the SFCT decreased by 11.09 ± 22.36 μm during the 2-year follow-up (p = 0.007). In contrast, in the patient group, CMT and SFCT decreased by 62.52 ± 71.45 and 27.25 ± 41.97 μm, respectively, showing a significant difference from the control group (p < 0.001 and p = 0.043, respectively). Both before surgery and at 1 year postoperatively, the thinner the CMT, the better the best-corrected visual acuity (BCVA) (p = 0.010 and p = 0.018, respectively). A better postoperative BCVA at 2 years was associated with a thinner CMT and better BCVA before surgery (p < 0.001 and p < 0.001, respectively).Conclusions: Following a phacovitrectomy procedure, ERM patients showed significant reductions in both the CMT and SFCT at the 2-year follow-up.

scholarly journals Long-Term Refractive Outcomes After Combined Phacoemulsification and Trabeculectomy in Glaucoma Patients

2020 ◽  
Author(s):  
Yeon Soo Kang ◽  
Mi Sun Sung ◽  
Hwan Heo ◽  
Yong Sok Ji ◽  
Sang Woo Park
Keyword(s):  
Risk Factors ◽  
Anterior Segment ◽  
Anterior Chamber Depth ◽  
Absolute Error ◽  
Refractive Outcome ◽  
Refractive Outcomes ◽  
Corrected Visual Acuity ◽  
Before And After ◽  
The Mean

Abstract Background: To investigate long-term refractive outcomes after phacotrabeculectomy and to determine risk factors that may cause unstable refractive outcomes after phacotrabeculectomy in glaucoma patients.Methods: A total 120 eyes of 120 patients who had underwent uncomplicated phacotrabeculectomy (combined group) or phacoemulsification (phaco-only group) were included. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) were measured before and after surgery, and anterior segment parameters including anterior chamber depth (ACD), lens vault (LV), and anterior vault (AV) measured using anterior-segment optical coherence tomography were compared between the two groups. The mean absolute error (MAE) at 3, 6, 12, and 24 months postoperatively were compared. Risk factors associated with unstable refractive outcomes (MAE ≥ 0.5) were investigated in the combined group.Results: In both groups, BCVA was improved and IOP was decreased significantly. MAE at 3, 6, 12, 24 months postoperatively were not significantly different between two groups. The risk factors for unstable refractive outcomes after 12 months of phacotrabeculectomy were old age and LV. Whereas, the only factor predicting unstable refractive outcome after 24 months of phacotrabeculectomy was LV. The cut-off value of LV for predicting unstable refractive outcome analyzed by the ROC curve was 0.855 mm.Conclusions: Phacotrabeculectomy may be an effective treatment with predictable long-term refractive outcomes similar to phacoemulsification in patients with glaucoma. However, elderly patients or patients with large LV may be predisposed to unpredictable postoperative refractive outcomes after phacotrabeculectomy.

Toric intraocular lens for correction of high corneal astigmatism in cataract patients

2020 ◽  
Vol 1 (2) ◽  
pp. 83-88
Author(s):  
Irene Simo ◽  
◽  
Laura Remón ◽  
Keyword(s):  
Visual Acuity ◽  
Intraocular Lens ◽  
Medical Engineering ◽  
Toric Intraocular Lens ◽  
Toric Iol ◽  
Corrected Visual Acuity ◽  
Uncorrected Visual Acuity ◽  
Before And After ◽  
The Mean ◽  
Axis Rotation

AIM: To evaluate the efficacy of Bi-Flex toric intraocular lens (T-IOL; Medicontur, Medical Engineering, Ltd., Inc.) implantation to correct preexisting astigmatism in patients having cataract surgery. METHODS: This retrospective consecutive study included 22 eyes of 16 patients with more than 2.50 diopters (D) of corneal preexisting astigmatism having cataract. Preoperative and postoperative uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), objective and subjective refraction and keratometric and topographic cylinder were measured. Postoperative the toric IOL axis was evaluated using vector analysis. RESULTS: Postoperatively, subjective refractive cylinder was reduced significant (P<0.05) from 4.05±1.53 D to 1.35±0.86 D. The component J0 reduced in magnitude from -0.81±2.02 D to -0.12±0.62 D (P<0.05). Both, UCVA and BCVA improved significantly at 1mo after surgery (P<0.05 in both cases). After the surgery, the UCVA and BCVA were 0.24±0.19 and 0.06±0.08, respectively. The mean toric IOL axis rotation was 2.95±5.25 degree, with rotation less than 10 degrees in 86.36% of eyes. No differences in mean keratometric values obtained before and after surgery were found (P>0.05 for J0 and J45). CONCLUSION: Implantation of the Bi-Flex toric IOL is a safe and effective method to correct the preexisting regular astigmatism (greater than 2.50D).

scholarly journals Effect of axial length and age on the visual outcome of patients with idiopathic epiretinal membrane after pars plana vitrectomy

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Sakiko Minami ◽  
Hajime Shinoda ◽  
Yuta Shigeno ◽  
Norihiro Nagai ◽  
Toshihide Kurihara ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Axial Length ◽  
Epiretinal Membrane ◽  
Pars Plana Vitrectomy ◽  
Visual Outcome ◽  
Idiopathic Epiretinal Membrane ◽  
Corrected Visual Acuity ◽  
Pars Plana ◽  
The Mean ◽  
Clinical Records

AbstractWe evaluated predictive factors for visual outcomes in patients with idiopathic epiretinal membrane (iERM) after pars plana vitrectomy (PPV). Clinical records for 114 eyes (114 patients, mean age: 70.6 years) with iERM treated by PPV between March 2012 and March 2018 were retrospectively reviewed. Overall, the mean postoperative best-corrected visual acuity (BCVA) and central retinal thickness measured by optical coherence tomography improved as early as 1 month after surgery, and further improved until 3 months (P < 0.01). Multiple linear regression analyses adjusted for the preoperative BCVA showed that older age (B, 0.010; 95% confidence interval, 0.003 to 0.016; P = 0.003) and a shorter axial length (AL; B, −0.059; 95% confidence interval, −0.099 to −0.019; P = 0.005) predicted worse postoperative BCVA. The Mann-Whitney U test showed that the postoperative BCVA was worse in eyes with AL < 23.6 mm than in eyes with AL ≥ 23.6 mm (P = 0.037), and in patients aged ≥69 years than in patients aged <69 years (P = 0.024). The findings may help in evaluating surgical indications for each patient to obtain satisfactory outcomes, irrespective of the preoperative BCVA.

Successful Regression in Patients with Progressive Keratoconus by Corneal Crosslinking

2021 ◽  
Author(s):  
Tobias Röck ◽  
Eva-Maria Konrad ◽  
Daniel Röck ◽  
Matthias Bramkamp ◽  
Gunnar Blumenstock ◽  
...  
Keyword(s):  
Statutory Health Insurance ◽  
Observation Time ◽  
Collagen Crosslinking ◽  
Corrected Visual Acuity ◽  
Before And After ◽  
Study Population ◽  
Corneal Collagen Crosslinking ◽  
The Mean ◽  
The University ◽  
Corneal Collagen

Abstract Background Since 2019, corneal collagen crosslinking (CXL) is included in the catalog of procedures covered by statutory health insurance in Germany. CXL is an established ophthalmological procedure for the last 20 years. The aim of this investigation was the measurement of progression before and after CXL. Material und Methods 65 consecutive eyes with progressive keratoconus from 53 patients were included in the retrospective study, which were observed at the University Eye Hospital Tübingen at least two years before and at least two years after CXL. The time of observation took place from October 2009 until March 2018. Parameters of interest had been the best corrected visual acuity (BCVA) and the keratometric values from the elevation maps measured by a Scheimpflug camera. Results 65 eyes of 53 patients had been documented. The study population included 46 (86.8%) male and 7 (13.2%) female subjects. The mean age was 24 ± 8 years. The averaged observation time between the primary consultation and CXL showed 25 ± 15 months. Preoperatively the mean BCVA pointed out in a significant increase (0.13 ± 0.17 [first visit] vs. 0.23 ± 0.22 [preOP], p < 0.0001) while the mean Kmax resulted in a statistically significant increase (46.34 ± 3.33 dpt [first visit] vs. 48.78 ± 4.17 dpt [preOP], p < 0.0001). The mean thinnest point of the cornea showed a significant decrease (490.48 ± 34.23 µm [first visit] vs. 468.62 ± 29.84 µm [preop], p < 0.0001). Postoperatively the mean BCVA resulted in a significant improvement at the 12th postoperative month in comparison to the preoperative measurement (0.23 ± 0.22 [preOP] vs. 0.16 ± 0.14 [12 months], p = 0.04 respectively 0.17 ± 0.17 [24 months], p = 0.0006). The mean Kmax demonstrated in the 12th postoperative month a significant reduction (48.78 ± 4.17 dpt [preOP] vs. 47.91 ± 3.41 dpt [12 months], p = 0.0009 respectively 48 ± 4.56 dpt [24 months], p = 0.0051). The mean thinnest point of the cornea indicated a decrease at the 12th postoperative month (468.62 ± 29.84 µm [preOP] vs. 459.82 ± 35.88 µm [12 months], p = 0.0078 respectively 453.47 ± 43.39 µm [24 months], p = 0.0227). Conclusion CXL is a successful procedure for the therapy of progressive keratoconus.

scholarly journals Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy

2021 ◽  
Vol 10 (24) ◽  
pp. 5739
Author(s):  
Young-Joon Jeon ◽  
Jae-Hui Kim ◽  
Jong-Woo Kim ◽  
Chul-Gu Kim
Keyword(s):  
Polypoidal Choroidal Vasculopathy ◽  
Complete Resolution ◽  
Retinal Thickness ◽  
Treatment Options ◽  
Short Term ◽  
Corrected Visual Acuity ◽  
Before And After ◽  
The Mean ◽  
Choroidal Vasculopathy ◽  
Best Corrected Visual Acuity

Background: To evaluate the short-term outcomes of switching to ranibizumab in aflibercept-resistant polypoidal choroidal vasculopathy (PCV). Methods: This retrospective study included 18 eyes diagnosed with aflibercept-resistant PCV. All patients were treated with two to four consecutive ranibizumab injections at 4–5-week intervals. The best-corrected visual acuity (BCVA), and central retinal thickness (CRT) values before and after switching to ranibizumab were compared. The proportion of eyes showing ≥100 µm decrease in retinal thickness and/or complete resolution of fluid after switching was identified. Results: The mean number of aflibercept injections before switching was 5.7 ± 3.3. After switching, a mean of 2.8 ± 0.6 consecutive ranibizumab injections was performed. The mean logarithm of minimal angle of resolution (logMAR) BCVA was 0.41 ± 0.26 (Snellen equivalents = 20/51) before switching, and 0.40 ± 0.30 (20/50) after switching (p = 0.574). The mean CRT was 422.2 ± 152.4 µm before switching, and 400.7 ± 182.0 µm after switching (p = 0.236). A decrease in CRT of ≥100 µm, and/or complete resolution of fluid was noted in three eyes (16.7%). Conclusions: Switching to ranibizumab in aflibercept-resistant polypoidal choroidal vasculopathy was not effective in most patients, suggesting the need for further investigation to seek more effective treatment options for this condition.

Sign in / Sign up

Export Citation Format

Share Document